Guardians at the gate: patent protection for therapeutic monoclonal antibodies--part 1.

MAbs

Sterne, Kessler, Goldstein & Fox P.L.L.C., Washington DC 20005, USA.

Published: April 2010

Patents provide one of the few protections companies can avail themselves of to help protect their therapeutic monoclonal antibody products. Just as the therapeutic monoclonal antibody field is constantly evolving, so too is the legal environment surrounding these inventions. In a series of articles, the general state of the law surrounding therapeutic antibodies will be explained, and important challenges to this technology area will be discussed. Much is at stake when companies market therapeutic monoclonal antibodies; therefore, a firm understanding of this important form of protection is critically important for anyone developing such products.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726603PMC
http://dx.doi.org/10.4161/mabs.1.4.8860DOI Listing

Publication Analysis

Top Keywords

therapeutic monoclonal
16
monoclonal antibody
8
therapeutic
5
guardians gate
4
gate patent
4
patent protection
4
protection therapeutic
4
monoclonal
4
monoclonal antibodies--part
4
antibodies--part patents
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!